MiNK Therapeutics (INKT) Files for Up to $50M IPO

MiNK Therapeutics (NASDAQ: INKT) files for up to $50,000,000 IPO.

The company describes itself as: "We are a clinical stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress graft-versus-host-disease (GvHD). Our proprietary platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. As such, we believe that our approach represents a highly versatile application for therapeutic development in cancer and immune diseases. We are leveraging our platform and manufacturing capabilities to develop a wholly owned or exclusively licensed pipeline of both native and engineered iNKT cells, and anticipate having multiple clinical and preclinical readouts in 2021 and 2022."

Evercore ISI and William Blair will serve as lead underwriters.

You May Also Be Interested In

• Londian Wason New Energy Tech opens at $26, above IPO price of $22
• WhiteHawk Minerals posts Q2 results, declares dividend, signs $111.8M deals
• Patrick Bombach resigns from Mobileye board amid Intel departure